Pharmacological Analysis of the Effects of Benzodiazepines On

Total Page:16

File Type:pdf, Size:1020Kb

Pharmacological Analysis of the Effects of Benzodiazepines On Short report 81 Pharmacological analysis of the effects of benzodiazepines on punished schedule-induced polydipsia in rats Ricardo Pello´ n, Ana Ruı´z, Esmeralda Lamas and Cilia Rodrı´guez Food-deprived Wistar rats were exposed to a fixed-time rate-increasing effect of 0.3 mg/kg of diazepam, but at 60-s food delivery schedule until they developed schedule- 17.0mg/kg partially blocked such antipunishment effect. induced polydipsia. Every fifth lick was then followed by an Overall, the present results extend the similarities of electric shock during two, signalled, 5-min periods, which the effects of benzodiazepine compounds on adjunctive ran concurrently with the food delivery schedule. Shock and operant patterns of behaviour by showing similar intensities were adjusted to reduce licking to 60–70% of interactions within the benzodiazepine receptor the unpunished licking rates. The benzodiazepine full complex. Behavioural Pharmacology 18:81–87 c 2007 agonists, diazepam (0.3–3.0 mg/kg), chlordiazepoxide Lippincott Williams & Wilkins. (0.3–10.0 mg/kg), oxazepam (0.3–3.0 mg/kg) and the benzodiazepine partial agonist, RU-32698 (3.0–17.0 Behavioural Pharmacology 2007, 18:81–87 mg/kg), led to increases in punished responding at Keywords: benzodiazepine-receptor compounds, chlordiazepoxide, intermediate doses and decreases at the highest doses diazepam, flumazenil, oxazepam, punishment, rat, RU-32698, RU-34000, tested. All benzodiazepine agonists brought about dose- schedule-induced polydipsia dependent decreases in unpunished schedule-induced Animal Behaviour Laboratories, Department of Basic Psychology I, Faculty of polydipsia, with doses required to reduce drinking proving Psychology, National University for Distance Education (Universidad Nacional de higher than doses required to increase punished schedule- Educacio´ n a Distancia), Madrid, Spain. induced polydipsia. The antipunishment effect of 0.3 mg/kg of diazepam was dose-dependently antagonized by Correspondence to Dr Ricardo Pello´ n, PhD, Departamento de Psicologı´a flumazenil and the benzodiazepine inverse agonist, Ba´sica I, Facultad de Psicologı´a, Universidad Nacional de Educacio´ n a Distancia, C/ Juan del Rosal 10, Ciudad Universitaria, 28040-Madrid, Spain. RU-34000. Flumazenil effects, however, could reflect E-mail: [email protected] actions of flumazenil as a partial inverse agonist at GABAA receptors. RU-32698 at 10.0 mg/kg further facilitated the Received 26 May 2006 Accepted as revised 30 October 2006 Introduction receptor (see Rudolph et al., 2000). Such mediation can Benzodiazepines are highly effective compounds in the be investigated by blocking GABAA receptors with treatment of anxiety disorders (see Nutt, 2005). One of benzodiazepine antagonists, and then testing the absence the best documented behavioural effects of benzodiaze- or diminution of a previously observed effect by the pines is their anxiolytic action in conflict procedures. The targeted benzodiazepine agonist. In this connection, the operant response rate reduced by the simultaneous antipunishment effect of benzodiazepines and related occurrence of a schedule of positive reinforcement and compounds can be attenuated by previous administration a punishment schedule is selectively increased by of the benzodiazepine receptor antagonist, flumazenil substances with anxiolytic activity, notably benzodiaze- (e.g. Barrett et al., 1986; Witkin et al., 1997). pines (see Houser, 1978; Millan, 2003). Compared with the research undertaken on operant The antipunishment effect of benzodiazepines and other behaviour, very few studies have addressed the effects of anxiolytics depends on the intensity and frequency of the drugs on punished adjunctive behaviour. The term electric shocks that are used as punitive stimuli and ‘adjunctive behaviour’ refers to any behaviour that occurs determine the punished response rate; low unpunished during reinforcement schedules without any apparent operant response rates are not increased by anxiolytic drugs contingent relationship with the reinforcer, and would (McMillan, 1973; Jeffrey and Barrett, 1979; Dworkin correspond to behavioural patterns adjunctive to the et al., 1989). The degree of the antipunishment effect of operant behaviour needed to obtain the reinforcer. The benzodiazepines is linked to their clinical efficacy, with best studied adjunctive behaviour is schedule-induced positive correlations reported in studies with pigeons polydipsia in rats, that is, when an animal is deprived of (Kleven and Koek, 1999), rats (Cook and Davidson, food and is subjected to an intermittent reinforcement 1973) and rhesus monkeys (Rowlett et al., 2006). schedule of food presentation, then, if it is given access to water at the same time, it will drink great amounts of Behavioural effects of benzodiazepines appear to be liquid concurrently with its performance under the mediated by actions at different subtypes of GABAA reinforcement schedule (Falk, 1961). Schedule-induced 0955-8810 c 2007 Lippincott Williams & Wilkins Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 82 Behavioural Pharmacology 2007, Vol 18 No 1 polydipsia is adjunctive behaviour because the animals doses of the inverse benzodiazepine agonist, RU-34000 are neither thirsty nor do they have any need to drink to (Gardner and Budhram, 1991). The study of the obtain the food reinforcer. Despite formal distinctions pharmacological mediation of actions of benzodiazepines between adjunctive and operant behaviour, operant on punished schedule-induced polydipsia should provide contingencies have been postulated to be involved in further comparisons of adjunctive and operant behaviour the maintenance of schedule-induced polydipsia and to advance the understanding of the mechanisms adjunctive behaviour in general. Such thinking is derived involved in the development and maintenance of in part from studies showing similarities in the effects of adjunctive behaviour. drugs on adjunctive and operant patterns of behaviour (Pello´n and Flores, 2006). Methods Flores and Pello´n (1998) showed that adjunctive drinking Subjects reduced by contingent presentation of electric shocks Six experimentally naive, male Wistar rats, obtained from could be increased after administration of the benzo- IFFA-CREDO (Lyon, France), were used. They were diazepine, diazepam, but not after administration of approximately 90 days old and had a mean free-feeding weight of 414 g (range: 380–432 g) at the start of the buspirone or D-amphetamine. Moreover, this effect depended on the intensity of shock used, and was not experiment. The rats were individually housed and seen in animals that received noncontingent electric placed in a room with controlled environmental condi- 1 shocks upon licking. In a later study, Flores and Pello´n tions (ambient temperature 22 C, 60% relative humidity (2000) observed that the more adjunctive drinking was and an 08.00/20.00 h light/dark cycle). After a 10-day reduced by the use of electric shocks of different period of habituation to the living conditions, and before intensity, the greater was the antipunishment effect of training, the rats were gradually reduced to and main- diazepam. The procedure used by Flores and Pello´n tained at 80% of their ideal free-feeding weight through (2000) consisted of inducing adjunctive drinking in rats food restriction. Clean, fresh water was freely available in by means of a schedule that dispensed a food pellet every all animals’ home cages. These procedures were in 60 s regardless of the animals’ behaviour [a fixed-time accordance with European Union Directive 2003/65/EC (FT) schedule], and alternating this schedule with and Spanish Royal Decree 1201/2005 governing the another which, in addition to food, dispensed electric protection of animals used for experimental purposes. shocks contingent on every fifth lick. Indeed, this procedure, based on the presentation of alternate punish- Apparatus ment and nonpunishment components, was the one The experiment was conducted in six, identical 29 Â followed in the present experimental series. 24.7 Â 35.5 cm, LI-836 rodent conditioning chambers (Letica Instruments, Barcelona, Spain) with grid floors. The chambers were enclosed in a soundproofed housing. Unlike the punishment studies outlined above, moderate The front panel of each chamber was made of aluminium, doses of benzodiazepine increase unpunished adjunctive the right-hand wall of black Plexiglas, and the remaining drinking, though mainly in terms of water intake rather sides and roof of transparent Plexiglas. Scrambled than licking (Bacotti and Barrett, 1976; Sanger and electric shocks were administered via each chamber’s Blackman, 1976; Pello´n et al., 1992), a finding that grid floor, by six independent LI 200–20 generators, suggests that benzodiazepines might alter the topography (Letica Instruments, Barcelona, Spain). A calibrated of drinking. water bottle was attached to the external side of the right wall of each chamber, with its spout accessible to This study sought to investigate the pharmacological the rat through a 3.2 Â 3.9 cm aperture, located 20 cm mechanisms of action of benzodiazepines on punished from the front wall and 7 cm above the floor. The spout schedule-induced polydipsia, by the comparative study of was positioned 2 cm behind the aperture, in such a way different benzodiazepine agonists and the possible that the rat could lick, but not maintain permanent antagonism through the blockade of benzodiazepine
Recommended publications
  • Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Guaiana, G., Barbui, C., Caldwell, D. M., Davies, S. J. C., Furukawa, T. A., Imai, H., ... Cipriani, A. (2017). Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(7), [CD012729]. https://doi.org/10.1002/14651858.CD012729 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD012729 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012729/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Cochrane Database of Systematic Reviews Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol) Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 7.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • TR-468: Oxazepam (CASRN 604-75-1) in F344/N Rats
    NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF OXAZEPAM (CAS NO. 604-75-1) IN F344/N RATS (FEED STUDIES) NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 October 1998 NTP TR 468 NIH Publication No. 99-3958 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health FOREWORD The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation. The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease. The studies described in this Technical Report were performed under the direction of the NIEHS and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Contents and Note to the Reader
    CONTENTS NOTE TO THE READER ................. ..... ................................................................... .........1 LIST OF PARTICIPANTS ..... ...................... ................ ..................... .............. ...... .............3 PREAMBLE Background................................................ .................... ... .................................. ............7 Objective and Scope ............ ..................... ................ ................... ................ ................... 7 Selection of Topics for Monographs............................ ............ ....... ................... ......... .... 8 Data for Monographs ........................................ ................ ..............................................9 The W orking Group.......... ...... .................. ....... .......... ........ .............. ................. ..............9 W orking Procedures..................................... ...................................... .............................9 Exposure Data.............. ....... ...... ......... ...... ............................................ ............... ..... ..... 10 . Studies of Cancer in Humans........................................................................................12 Studies of Cancer in Experimental AnimaIs ................................ ................................. i 5 Other Data Relevant to an Evaluation of Carcinogenicity and Its Mechanisms...........18 Summary of Data Reported .... ..... .................... ........ ..
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Appendix 1 Cross-Reference of Research, Generic and Trade Names of Benzodiazepines
    Appendix 1 Cross-Reference of Research, Generic and Trade Names of Benzodiazepines Table 1. Benzodiazepine research designations with corresponding generic names Research Designation Generic Name lactam demoxepam methyloxazepam temazepam A 101 nordazepam AB 35616 clorazepate AB 39083 clorazepate AH 3232 clorazepate CB 4261 tetrazepam CB 4306 clorazepate CB 4311 clorazepate CGS 8216 (antagonist) CI683 ripazepam CS 370 cloxazolam CS 430 haloxazolam D40TA estazolam EGYT 341 tofisopam ER 115 temazepam HR 158 loprazolam HR376 clobazam HR 4723 clobazam HR930 fosazepam K3917 temazepam 287 THE BENZODIAZEPINES Research Designation Generic Name LA 111 diazepam LM 2717 clobazam ORF 8063 triflubazam Ro 4-5360 nitrazepam Ro 5-0690 chlordiazepoxide Ro 5-0883 desmethy1chlordiazepoxide Ro 5-2092 demoxepam Ro 5-2180 desmethyldiazepam Ro 5-2807 diazepam Ro 5-2925 desmethylmedazepam Ro 5-3059 nitrazepam Ro 5-3350 bromazepam Ro 5-3438 fludiazepam Ro 5-4023 clonazepam Ro 5-4200 flunitrazepam Ro 5-4556 medazepam Ro 5-5345 temazepam Ro 5-6789 oxazepam Ro 5-6901 flurazepam Ro 15-1788 (antagonist) Ro 21-3981 midazolam RU 31158 loprazolam S 1530 nimetazepam SAH 1123 isoquinazepam SAH 47603 temazepam SB 5833 camazepam SCH 12041 halazepam SCH 16134 quazepam U 28774 ketazolam U 31889 alprazolam U 33030 triazolam W4020 prazepam We 352 triflubazam 288 RESEARCH, GENERIC AND TRADE NAMES Research Designation Generic Name We 941 brotizolam Wy 2917 temazepam Wy 3467 diazepam Wy 3498 oxazepam Wy 3917 temazepam Wy 4036 lorazepam Wy 4082 lormetazepam Wy 4426 oxazepam Y 6047
    [Show full text]
  • List of Benzodiazepines - Wikipedia, the Free Encyclopedia
    List of benzodiazepines - Wikipedia, the free encyclopedia Log in / create account Article Talk Read Edit Our updated Terms of Use will become effective on May 25, 2012. Find out more. List of benzodiazepines From Wikipedia, the free encyclopedia Main page The below tables contain a list of benzodiazepines that Benzodiazepines Contents are commonly prescribed, with their basic pharmacological Featured content characteristics such as half-life and equivalent doses to other Current events benzodiazepines also listed, along with their trade names and Random article primary uses. The elimination half-life is how long it takes for Donate to Wikipedia half of the drug to be eliminated by the body. "Time to peak" Interaction refers to when maximum levels of the drug in the blood occur Help after a given dose. Benzodiazepines generally share the About Wikipedia same pharmacological properties, such as anxiolytic, Community portal sedative, hypnotic, skeletal muscle relaxant, amnesic and Recent changes anticonvulsant (hypertension in combination with other anti The core structure of benzodiazepines. Contact Wikipedia hypertension medications). Variation in potency of certain "R" labels denote common locations of effects may exist among individual benzodiazepines. Some side chains, which give different Toolbox benzodiazepines produce active metabolites. Active benzodiazepines their unique properties. Print/export metabolites are produced when a person's body metabolizes Benzodiazepine the drug into compounds that share a similar pharmacological
    [Show full text]
  • AB 2588 EICG Appendix a Combined List of Substances
    AB 2588 EICG Regulation Appendix A - PRELIMINARY DRAFT PROPOSAL FOR PUBLIC REVIEW Overview of Proposed Additions to AB2588's Emission Inventory Criteria and Guidelines Regulation, Appendix A CARB requirements, by statute (Health & Safety Code Section 44300) The AB 2588 Air Toxics “Hot Spots” Program (Statute; Health and Safety Code (H&SC) Sections 44300) requires CARB to compile and maintain a list of substances for assessing toxic air pollutants. In our assessment, we consider specific international, national, state, and other lists of chemicals explicitly referenced in the Statute, as well as under our own CARB authority. There are seven sources from which the chemical substances are required to be considered for inclusion on the Hot Spots list. (1) CARB’s Toxic Air Contaminants (TACs) (2) US EPA Hazardous Air Pollutants (HAPs) (3) International Agency for Research on Cancer (IARC) (4) Proposition 65 (5) National Toxicology Program (NTP) (6) Hazard Evaluation System and Information Service (HESIS) (7) Explicit provision of CARB authority By statute, CARB is required to list all of the chemical substances found in the list above in Appendix A of the EICG, unless the substance meets the following criteria: (1) No evidence exists that it has been detected in the air (2) The substance is not manufactured or used in California CARB has divided the list into three appendices as described here: A-I are substances for which emissions are required to be quantified A-II are substances for which production, use, or other presence must be reported A-III are substances which need not be reported unless manufactured by the facility Additional information Over the past decade, many new chemical substances have emerged.
    [Show full text]